# **Special Issue**

# Artificial Intelligence for Network-Based Oncomarker Discovery and Cancer Prediction

Message from the Guest Editor

The discovery of reliable biomarkers, or oncomarkers, remains one of the central challenges in oncology, with profound implications for early detection, prognosis, and personalised treatment strategies. While traditional biomarker studies have provided important insights, they often focus on individual molecules rather than the complex biological networks driving cancer initiation and progression.

By integrating genomics, transcriptomics, proteomics, epigenomics, and metabolomics, AI methods can uncover novel molecular interactions, dysregulated pathways, and predictive signatures that may remain hidden in conventional analyses. In particular, graph neural networks (GNNs), network embeddings, and systems biology-inspired approaches hold promise for identifying prognostic and predictive oncomarkers, and informing clinical decision support in oncology.

The aim of this Special Issue is to bring together cuttingedge research and comprehensive reviews on the applications of AI for network-based biomarker discovery and cancer prediction. We welcome contributions that explore computational innovations and translational insights with clinical relevance.

### **Guest Editor**

Dr. Oleg Blyuss

Wolfson Institute of Population Health, Queen Mary University of London, London, UK

### Deadline for manuscript submissions

10 May 2026



## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/254115

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

#### **Author Benefits**

#### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

